Trademark Overview
On Friday, January 17, 2025, a trademark application was filed for PREDIDIAB PRÉDIRE POUR PRÉVENIR with the United States Patent and Trademark Office. The USPTO has given the PREDIDIAB PRÉDIRE POUR PRÉVENIR trademark a serial number of 79419015. The federal status of this trademark filing is NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER as of Thursday, March 13, 2025. This trademark is owned by PrédiDiab. The PREDIDIAB PRÉDIRE POUR PRÉVENIR trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:
Pharmaceutical and veterinary products sold on prescription or over the counter; sanitary products for medicine; dietetic substances for medical use; chemical preparations for medical or pharmaceutical use; vaccines; food for babies; plasters, material for dressings; disinfectants; vitamins, vitamin-based preparations, dietetic substances for medical use; natural dietetic foods and remedies based on medicinal plants for medical or veterinary use; beverages and foodstuffs for medicinal use; food supplements and additives for medicinal use; mineral food supplements for medicinal use; nutritional supplements, plant-based preparations for medicinal use; food supplements containing proteins, carbohydrates, lipids and/or fibers, or micronutrients such as vitamins and/or minerals, amino acids and/or fatty acids, for medical use; plant-based products and plant extracts for medicinal use; preparations for making dietetic or medicated beverages; medicinal preparations; chemical preparations for ...
Scientific and technological services, and also assorted development and design; medical and pharmacological research services; development of pharmaceutical products, carrying out evaluations of pharmaceutical products, carrying out testing on pharmaceutical products, laboratory research services concerning pharmaceutical products; computer programming in the medical field; advisory services for professionals and patients in the field of diabetes; management of data for medical use; information and advisory services; providing scientific and pharmaceutical expertise.
